Risankizumab

Topic
Thing
Risankizumab also known by the substance codes as BI-655066 and ABBV-066 or the trade name Skyrizi is a humanized monoclonal antibody targeting interleukin 23A. Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie.
Risankizumab
Definition
Risankizumab also known by the substance codes as BI-655066 and ABBV-066 or the trade name Skyrizi is a humanized monoclonal antibody targeting interleukin 23A. Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie.
Risankizumab
Risankizumab
Risankizumab also known by the substance codes as BI-655066 and ABBV-066 or the trade name Skyrizi is a humanized monoclonal antibody targeting interleukin 23A. Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie.
New to Cofactor?

Cofactor is a large, structured listing of people, places, and things. Here you can find the definition of each subject.

Your Cofactor profile
Sign up for an account to create your personal profile.